Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma.

Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma.

Dysregulation of the seven-transmembrane (7TM) receptor Smoothened (SMO) and other components of the Hedgehog (Hh) signaling pathway contributes to the development of cancers including basal cell carcinoma (BCC) and medulloblastoma (MB). However, SMO-specific antagonists produced mixed results in cl...

Full description

Bibliographic Details
Main Authors: Kirti Kandhwal Chahal, Jie Li, Irina Kufareva, Milind Parle, Donald L Durden, Robert J Wechsler-Reya, Clark C Chen, Ruben Abagyan
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0214901

Internet

https://doi.org/10.1371/journal.pone.0214901

Similar Items